ImmuCell/$ICCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmuCell
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Ticker
$ICCC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
71
ISIN
US4525253062
Website
ImmuCell Metrics
BasicAdvanced
$60M
-
-$0.03
0.24
-
Price and volume
Market cap
$60M
Beta
0.24
52-week high
$7.01
52-week low
$4.28
Average daily volume
23K
Financial strength
Current ratio
4.118
Quick ratio
2.07
Long term debt to equity
44.016
Total debt to equity
50.56
Interest coverage (TTM)
0.34%
Management effectiveness
Return on assets (TTM)
0.26%
Return on equity (TTM)
-1.01%
Valuation
Price to revenue (TTM)
2.073
Price to book
2.07
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
71.767
Growth
Revenue change (TTM)
28.29%
Earnings per share change (TTM)
-93.71%
3-year revenue growth (CAGR)
8.91%
3-year earnings per share growth (CAGR)
-34.37%
ImmuCell News
AllArticlesVideos
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
GlobeNewsWire·1 day ago
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewsWire·3 weeks ago
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmuCell stock?
ImmuCell (ICCC) has a market cap of $60M as of June 06, 2025.
What is the P/E ratio for ImmuCell stock?
The price to earnings (P/E) ratio for ImmuCell (ICCC) stock is 0 as of June 06, 2025.
Does ImmuCell stock pay dividends?
No, ImmuCell (ICCC) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next ImmuCell dividend payment date?
ImmuCell (ICCC) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmuCell?
ImmuCell (ICCC) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.